{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:14:52Z","timestamp":1790738092668,"version":"4.1.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006601","name":"Ministero degli Affari Esteri e della Cooperazione Internazionale","doi-asserted-by":"publisher","award":["PGR00978"],"award-info":[{"award-number":["PGR00978"]}],"id":[{"id":"10.13039\/501100006601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","award":["BOSD_RILO_17_01"],"award-info":[{"award-number":["BOSD_RILO_17_01"]}],"id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","award":["BOSD_RILO_18_01"],"award-info":[{"award-number":["BOSD_RILO_18_01"]}],"id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","award":["LOLM_RILO_17_01"],"award-info":[{"award-number":["LOLM_RILO_17_01"]}],"id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","award":["LOLM_RILO_18_01"],"award-info":[{"award-number":["LOLM_RILO_18_01"]}],"id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["118\u2013122"],"award-info":[{"award-number":["118\u2013122"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["NCT02856178"],"award-info":[{"award-number":["NCT02856178"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["NCT03036046"],"award-info":[{"award-number":["NCT03036046"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejmech.2019.111681","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T12:29:02Z","timestamp":1568291342000},"page":"111681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Dihydroorotate dehydrogenase inhibitors in anti-infective drug research"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4929-4460","authenticated-orcid":false,"given":"Donatella","family":"Boschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese Chiara","family":"Pippione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sainas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-3163","authenticated-orcid":false,"given":"Marco L.","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111681_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-physiol-021115-105031","article-title":"Supramolecular organization of respiratory complexes","volume":"78","author":"Enriquez","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejmech.2019.111681_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/br.34.3.278-343.1970","article-title":"Pyrimidine metabolism in microorganisms","volume":"34","author":"O'Donovan","year":"1970","journal-title":"Bacteriol. Rev."},{"key":"10.1016\/j.ejmech.2019.111681_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/jmbi.1998.2293","article-title":"Novel organization and sequences of five genes encoding all six enzymes for de novo pyrimidine biosynthesis in Trypanosoma cruzi","volume":"285","author":"Gao","year":"1999","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.111681_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00284-015-0826-6","article-title":"Accumulation of pyrimidine intermediate orotate decreases virulence factor production in Pseudomonas aeruginosa","volume":"71","author":"Niazy","year":"2015","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.ejmech.2019.111681_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.bi.49.070180.001345","article-title":"Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis","volume":"49","author":"Jones","year":"1980","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2019.111681_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.abb.2017.06.019","article-title":"The dihydroorotate dehydrogenases: past and present","volume":"632","author":"Reis","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2019.111681_bib7","doi-asserted-by":"crossref","first-page":"10881","DOI":"10.1021\/bi800413r","article-title":"Structures of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with substrates and products: atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction","volume":"47","author":"Inaoka","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111681_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/2211-5463.12403","article-title":"Crystal structures of FMN-bound and FMN-free forms of dihydroorotate dehydrogenase from Trypanosoma brucei","volume":"8","author":"Kubota","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2019.111681_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0969-2126(00)00530-X","article-title":"Structure of dihydroorotate dehydrogenase B: electron transfer between two flavin groups bridged by an iron-sulphur cluster","volume":"8","author":"Rowland","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.111681_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pep.2006.02.010","article-title":"Cloning, expression, purification, and characterization of Leishmania major dihydroorotate dehydrogenase","volume":"48","author":"Feliciano","year":"2006","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ejmech.2019.111681_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1107\/S2053230X15000886","article-title":"Recombinant production, crystallization and crystal structure determination of dihydroorotate dehydrogenase from Leishmania (Viannia) braziliensis","volume":"71","author":"Reis","year":"2015","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"10.1016\/j.ejmech.2019.111681_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/abbi.2000.1769","article-title":"A\u00a0second dihydroorotate dehydrogenase (Type A) of the human pathogen Enterococcus faecalis: expression, purification, and steady-state kinetic mechanism","volume":"377","author":"Marcinkeviciene","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2019.111681_bib13","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1111\/j.1742-4658.2006.05327.x","article-title":"Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans","volume":"273","author":"Zameitat","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2019.111681_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00239-004-0078-8","article-title":"The origin of dihydroorotate dehydrogenase genes of kinetoplastids, with special reference to their biological significance and adaptation to anaerobic, parasitic conditions","volume":"60","author":"Annoura","year":"2005","journal-title":"J.\u00a0Mol. Evol."},{"key":"10.1016\/j.ejmech.2019.111681_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbrc.2008.02.074","article-title":"Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain","volume":"369","author":"Pinheiro","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2019.111681_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0969-2126(97)00182-2","article-title":"The crystal structure of the flavin containing enzyme dihydroorotate dehydrogenase A from Lactococcus lactis","volume":"5","author":"Rowland","year":"1997","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.111681_bib17","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1128\/jb.176.13.3975-3982.1994","article-title":"Two different dihydroorotate dehydrogenases in Lactococcus lactis","volume":"176","author":"Andersen","year":"1994","journal-title":"J.\u00a0Bacteriol."},{"key":"10.1016\/j.ejmech.2019.111681_bib18","doi-asserted-by":"crossref","first-page":"29359","DOI":"10.1074\/jbc.271.46.29359","article-title":"The B form of dihydroorotate dehydrogenase from Lactococcus lactis consists of two different subunits, encoded by the pyrDb and pyrK genes, and contains FMN, FAD, and [FeS] redox centers","volume":"271","author":"Nielsen","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.biochi.2012.04.003","article-title":"Crystal structure of dihydroorotate dehydrogenase from Leishmania major","volume":"94","author":"Cordeiro","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2019.111681_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2958.2008.06131.x","article-title":"Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies","volume":"68","author":"Arakaki","year":"2008","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2019.111681_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1107\/S1744309110048414","article-title":"Structure of the putative dihydroorotate dehydrogenase from Streptococcus mutans","volume":"67","author":"Liu","year":"2011","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"10.1016\/j.ejmech.2019.111681_bib22","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1021\/bi001111d","article-title":"Dihydroorotate dehydrogenase from Clostridium oroticum is a class 1B enzyme and utilizes a concerted mechansim of catalysis","volume":"39","author":"Argyrou","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111681_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/abbi.1999.1455","article-title":"Biochemical characterization of the heteromeric Bacillus subtilis dihydroorotate dehydrogenase and its isolated subunits","volume":"371","author":"Kahler","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2019.111681_bib24","doi-asserted-by":"crossref","first-page":"13129","DOI":"10.1021\/bi990674q","article-title":"Dihydroorotate dehydrogenase B of Enterococcus faecalis. Characterization and insights into chemical mechanism","volume":"38","author":"Marcinkeviciene","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111681_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0969-2126(00)00077-0","article-title":"Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents","volume":"8","author":"Liu","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.111681_bib26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0965-1748(02)00052-8","article-title":"Drosophila melanogaster dihydroorotate dehydrogenase: the N-terminus is important for biological function in\u00a0vivo but not for catalytic properties in\u00a0vitro","volume":"32","author":"L\u00f6ffler","year":"2002","journal-title":"Insect Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.111681_bib27","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1021\/bi900370s","article-title":"Roles in binding and chemistry for conserved active site residues in the class 2 dihydroorotate dehydrogenase from Escherichia coli","volume":"48","author":"Fagan","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111681_bib28","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1432-1327.2000.01213.x","article-title":"Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase","volume":"267","author":"Rawls","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2019.111681_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006859115450","article-title":"Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides","volume":"174","author":"Loffler","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2019.111681_bib30","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.1073\/pnas.0910885107","article-title":"Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway","volume":"107","author":"Khutornenko","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2019.111681_bib31","doi-asserted-by":"crossref","first-page":"33373","DOI":"10.1074\/jbc.M004451200","article-title":"Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis","volume":"275","author":"Copeland","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1248\/cpb.c17-00796","article-title":"Dihydroorotate dehydrogenase as a target for the development of novel Helicobacter pylori-specific antimicrobials","volume":"66","author":"Ohishi","year":"2018","journal-title":"Chem. Pharmaceut. Bull."},{"key":"10.1016\/j.ejmech.2019.111681_bib33","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2019.111681_bib34","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/jac\/dkx065","article-title":"Dihydroorotate dehydrogenase inhibitor F901318 has potent in\u00a0vitro activity against Scedosporium species and Lomentospora prolificans","volume":"72","author":"Wiederhold","year":"2017","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib35","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/IAI.00187-16","article-title":"Pyrimidine pathway-dependent and -independent functions of the Toxoplasma gondii mitochondrial dihydroorotate dehydrogenase","volume":"84","author":"Hortua","year":"2016","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2019.111681_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.biochi.2019.01.006","article-title":"Structural basis for the design of selective inhibitors for Schistosoma mansoni dihydroorotate dehydrogenase","volume":"158","author":"Nonato","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2019.111681_bib37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.111681_bib38","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection","volume":"17","author":"Sulyok","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.111681_bib39","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.ejmech.2010.09.055","article-title":"Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery","volume":"45","author":"Cheleski","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejmech.2018.08.033","article-title":"Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase","volume":"157","author":"Chibli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1371\/journal.pone.0125829","article-title":"Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method","volume":"10","author":"Yoshino","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111681_bib42","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.bmc.2017.01.009","article-title":"Design and synthesis of potent substrate-based inhibitors of the Trypanosoma cruzi dihydroorotate dehydrogenase","volume":"25","author":"Inaoka","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1107\/S174430910502659X","article-title":"Expression, purification and crystallization of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with orotate","volume":"61","author":"Inaoka","year":"2005","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"10.1016\/j.ejmech.2019.111681_bib44","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1021\/jm020112w","article-title":"Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase","volume":"45","author":"Haque","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ja.2013.42","article-title":"Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2","volume":"66","author":"Kawada","year":"2013","journal-title":"J.\u00a0Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2019.111681_bib46","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1016\/j.tet.2013.05.033","article-title":"Structure\u2013activity relationship study of intervenolin derivatives: synthesis, antitumor, and anti-Helicobacter pylori activities","volume":"69","author":"Abe","year":"2013","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.111681_bib47","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/jm200592f","article-title":"Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential","volume":"54","author":"Coteron","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib48","doi-asserted-by":"crossref","first-page":"17980","DOI":"10.1074\/jbc.M114.558353","article-title":"In\u00a0vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth","volume":"289","author":"Ross","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib49","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/jm500481t","article-title":"Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors","volume":"57","author":"Deng","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A\u00a0long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2019.111681_bib51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1107\/S2053230X15000989","article-title":"The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions","volume":"71","author":"Deng","year":"2015","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"10.1016\/j.ejmech.2019.111681_bib52","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1021\/acs.jmedchem.6b00275","article-title":"Tetrahydro-2-naphthyl and 2-indanyl triazolopyrimidines targeting plasmodium falciparum dihydroorotate dehydrogenase display potent and selective antimalarial activity","volume":"59","author":"Kokkonda","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib53","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acsinfecdis.6b00144","article-title":"A\u00a0triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria","volume":"2","author":"Phillips","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.111681_bib54","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1021\/acsomega.8b01573","article-title":"Isoxazolopyrimidine-based inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity","volume":"3","author":"Kokkonda","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2019.111681_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejmech.2018.11.044","article-title":"Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: synthesis, biological evaluation and X-ray structural studies","volume":"163","author":"Pippione","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib56","doi-asserted-by":"crossref","first-page":"26999","DOI":"10.1074\/jbc.M109.028589","article-title":"Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds","volume":"284","author":"Deng","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib57","doi-asserted-by":"crossref","first-page":"33054","DOI":"10.1074\/jbc.M110.162081","article-title":"Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model","volume":"285","author":"Booker","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib58","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1021\/jm300157n","article-title":"Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases","volume":"55","author":"Bedingfield","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1107\/S0907444905042642","article-title":"Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor","volume":"62","author":"Hurt","year":"2006","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2019.111681_bib60","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.4155\/fmc-2017-0250","article-title":"Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria","volume":"10","author":"Hoelz","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejmech.2016.09.085","article-title":"Dihydroorotate dehydrogenase: a drug target for the development of antimalarials","volume":"125","author":"Singh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib62","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acsmedchemlett.7b00030","article-title":"Discovery of antimalarial azetidine-2-carbonitriles that inhibit P. Falciparum dihydroorotate dehydrogenase","volume":"8","author":"Maetani","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111681_bib63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molbiopara.2013.05.008","article-title":"Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii","volume":"190","author":"Hegewald","year":"2013","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2019.111681_bib64","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1110\/ps.03533004","article-title":"Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain","volume":"13","author":"Hansen","year":"2004","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2019.111681_bib65","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1021\/acs.jmedchem.8b00373","article-title":"Targeting myeloid differentiation using potent 2-hydroxypyrazolo[1,5- a]pyridine scaffold-based human dihydroorotate dehydrogenase inhibitors","volume":"61","author":"Sainas","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib66","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fphar.2018.00997","article-title":"Selective cytotoxicity of dihydroorotate dehydrogenase inhibitors to human cancer cells under hypoxia and nutrient-deprived conditions","volume":"9","author":"Miyazaki","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111681_bib67","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1021\/acs.jmedchem.7b01862","article-title":"Design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase","volume":"61","author":"Madak","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib68","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41467-018-03441-3","article-title":"A\u00a0DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage","volume":"9","author":"Ladds","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.111681_bib69","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/acsmedchemlett.6b00316","article-title":"Development of ML390: a human dhodh inhibitor that induces differentiation in acute myeloid leukemia","volume":"7","author":"Lewis","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111681_bib70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/ml300464h","article-title":"SAR based optimization of a 4-quinoline carboxylic acid analog with potent anti-viral activity","volume":"4","author":"Das","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111681_bib71","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1016\/j.bmcl.2011.10.052","article-title":"Biaryl analogues of teriflunomide as potent DHODH inhibitors","volume":"21","author":"Erra","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111681_bib72","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/cmdc.200900454","article-title":"Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection","volume":"5","author":"Fritzson","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111681_bib73","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bmcl.2010.01.115","article-title":"Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures","volume":"20","author":"McLean","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111681_bib74","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1021\/jm800963t","article-title":"Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases","volume":"52","author":"Davies","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib75","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1574892812666171108124218","article-title":"Use of human dihydroorotate dehydrogenase (hDHODH) inhibitors in autoimmune diseases and new perspectives in cancer therapy","volume":"13","author":"Lolli","year":"2018","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111681_bib76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2018.10.012","article-title":"Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer","volume":"195","author":"Madak","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.111681_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1358\/dof.2018.043.11.2856492","article-title":"DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents","volume":"43","author":"Sainas","year":"2018","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2019.111681_bib78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00126334-200110010-00016","article-title":"Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors","volume":"28","author":"Hossain","year":"2001","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2019.111681_bib79","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00002030-200307250-00005","article-title":"Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea","volume":"17","author":"Schlapfer","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2019.111681_bib80","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00007890-199909270-00014","article-title":"Novel mechanism od inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide","volume":"68","author":"Waldman","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.ejmech.2019.111681_bib81","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1128\/AAC.00561-10","article-title":"Characterization of dengue virus resistance to brequinar in cell culture","volume":"54","author":"Qing","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib82","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1128\/JVI.02510-10","article-title":"Inhibition of dengue virus through suppression of host pyrimidine biosynthesis","volume":"85","author":"Wang","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.111681_bib83","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.antiviral.2013.10.003","article-title":"Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis","volume":"100","author":"Marschall","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.111681_bib84","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/jm501446r","article-title":"Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH)","volume":"58","author":"Munier-Lehmann","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib85","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/acs.jmedchem.5b00606","article-title":"Original 2-(3-alkoxy-1H-pyrazol-1-yl)azines inhibitors of human dihydroorotate dehydrogenase (DHODH)","volume":"58","author":"Lucas-Hourani","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib86","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2018.08.012","article-title":"Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses","volume":"158","author":"Luthra","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.111681_bib87","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nchembio.2050","article-title":"Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification","volume":"12","author":"Deans","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.111681_bib88","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: a review","volume":"6","author":"Torres-Guerrero","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.ejmech.2019.111681_bib89","doi-asserted-by":"crossref","first-page":"9872095","DOI":"10.1155\/2018\/9872095","article-title":"Current visceral leishmaniasis research: a research review to inspire future study","volume":"2018","author":"Bi","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2019.111681_bib90","series-title":"Drug Targets in Kinetoplastid Parasites","first-page":"141","article-title":"Purine and pyrimidine metabolism in Leishmania","author":"Carter","year":"2008"},{"key":"10.1016\/j.ejmech.2019.111681_bib91","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1107\/S1744309106038966","article-title":"Crystallization and preliminary X-ray diffraction analysis of Leishmania major dihydroorotate dehydrogenase","volume":"62","author":"Cordeiro","year":"2006","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"10.1016\/j.ejmech.2019.111681_bib92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.parint.2005.08.001","article-title":"Genetic diversity and kinetic properties of Trypanosoma cruzi dihydroorotate dehydrogenase isoforms","volume":"55","author":"Sariego","year":"2006","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ejmech.2019.111681_bib93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/acsmedchemlett.8b00498","article-title":"Triazolopyrimidines and imidazopyridines: structure-activity relationships and in\u00a0vivo efficacy for trypanosomiasis","volume":"10","author":"Nagendar","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111681_bib94","series-title":"Annual Reports in Medicinal Chemistry","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.armc.2018.08.001","article-title":"Targeting human onchocerciasis: recent advances beyond ivermectin","author":"Sainas","year":"2018"},{"key":"10.1016\/j.ejmech.2019.111681_bib95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/mmi.12001","article-title":"Stoking the drug target pipeline for human African trypanosomiasis","volume":"86","author":"Phillips","year":"2012","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2019.111681_bib96","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and clinical treatment of Chagas disease: a review","volume":"97","author":"Sales Junior","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2019.111681_bib97","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1021\/jm0506975","article-title":"Dual binding mode of a novel series of DHODH inhibitors","volume":"49","author":"Baumgartner","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib98","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2174\/138955711797247707","article-title":"Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors","volume":"11","author":"Vyas","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib99","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1021\/jm301848w","article-title":"On dihydroorotate dehydrogenases and their inhibitors and uses","volume":"56","author":"Munier-Lehmann","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib100","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1073\/pnas.1101143108","article-title":"Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis","volume":"108","author":"Hoffmann","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2019.111681_bib101","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/JVI.02275-13","article-title":"Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor","volume":"88","author":"Ortiz-Riano","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.111681_bib102","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.1017142108","article-title":"Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)","volume":"108","author":"Bonavia","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2019.111681_bib103","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2353\/ajpath.2010.091227","article-title":"4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice","volume":"176","author":"Kulkarni","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2019.111681_bib104","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1016\/j.bmcl.2005.07.053","article-title":"SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors","volume":"15","author":"Leban","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111681_bib105","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","article-title":"The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase","volume":"35","author":"Davis","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111681_bib106","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-3565(25)12093-4","article-title":"The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis","volume":"275","author":"Cherwinski","year":"1995","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2019.111681_bib107","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/41483","article-title":"The complete genome sequence of the gastric pathogen Helicobacter pylori","volume":"388","author":"Tomb","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111681_bib108","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/16495","article-title":"Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori","volume":"397","author":"Alm","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111681_bib109","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0006-2952(00)00348-8","article-title":"Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones","volume":"60","author":"Marcinkeviciene","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111681_bib110","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1021\/bi982352c","article-title":"The activity of Escherichia coli dihydroorotate dehydrogenase is dependent on a conserved loop identified by sequence homology, mutagenesis, and limited proteolysis","volume":"38","author":"Bj\u00f6rnberg","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111681_bib111","doi-asserted-by":"crossref","first-page":"19141","DOI":"10.1038\/srep19141","article-title":"Identification of a small molecule that simultaneously suppresses virulence and antibiotic resistance of Pseudomonas aeruginosa","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.111681_bib112","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1128\/iai.64.10.4401-4405.1996","article-title":"Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus","volume":"64","author":"D'Enfert","year":"1996","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2019.111681_bib113","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/EC.4.2.298-309.2005","article-title":"Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans","volume":"4","author":"Noble","year":"2005","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.ejmech.2019.111681_bib114","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/IAI.67.2.624-629.1999","article-title":"The URA5 gene is necessary for histoplasma capsulatum growth during infection of mouse and human cells","volume":"67","author":"Retallack","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2019.111681_bib115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.fgb.2014.06.003","article-title":"The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence","volume":"70","author":"de Gontijo","year":"2014","journal-title":"Fungal Genet. Biol."},{"key":"10.1016\/j.ejmech.2019.111681_bib116","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00191-16","article-title":"De novo pyrimidine biosynthesis connects cell integrity to amphotericin B susceptibility in Cryptococcus neoformans","volume":"1","author":"Banerjee","year":"2016","journal-title":"mSphere"},{"key":"10.1016\/j.ejmech.2019.111681_bib117","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-017-0805-2","article-title":"Drugs in clinical development for fungal infections","volume":"77","author":"Gonzalez-Lara","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2019.111681_bib118","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib119","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In\u00a0vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib120","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib121","first-page":"62","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","author":"Jorgensen","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib122","first-page":"62","article-title":"Effect of the novel antifungal drug F901318 (olorofim) on growth and viability of Aspergillus fumigatus","author":"du","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.111681_bib123","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijpara.2009.02.004","article-title":"Toxoplasmosis: a history of clinical observations","volume":"39","author":"Weiss","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejmech.2019.111681_bib124","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.molbiopara.2012.04.009","article-title":"Biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from Toxoplasma gondii","volume":"184","author":"Hortua Triana","year":"2012","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2019.111681_bib125","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejmech.2019.111681_bib126","series-title":"Neglected Diseases and Drug Discovery","first-page":"65","article-title":"Chapter 3 antimalarial agents targeting nucleotide synthesis and electron transport: insight from structural biology","author":"Phillips","year":"2012"},{"key":"10.1016\/j.ejmech.2019.111681_bib127","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2019.111681_bib128","first-page":"544","article-title":"Medicinal chemistry case history: discovery of the dihydroorate dehydrogenase inhibitor DSM265 as an antimalarial drug candidate","volume":"vol. III","author":"Phillips","year":"2017"},{"key":"10.1016\/j.ejmech.2019.111681_bib129","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.111681_bib130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejmech.2017.12.051","article-title":"Antimalarial naphthoquinones. Synthesis via click chemistry, in\u00a0vitro activity, docking to PfDHODH and SAR of lapachol-based compounds","volume":"145","author":"Brandao","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib131","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature19804","article-title":"Diversity-oriented synthesis yields novel multistage antimalarial inhibitors","volume":"538","author":"Kato","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111681_bib132","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.drudis.2015.04.010","article-title":"Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st century","volume":"20","author":"Lolli","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2019.111681_bib133","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1039\/c1md00118c","article-title":"N-Substituted salicylamides as selective malaria parasite dihydroorotate dehydrogenase inhibitors","volume":"2","author":"Fritzson","year":"2011","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2019.111681_bib134","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1039\/C5MD00182J","article-title":"Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches","volume":"6","author":"Pippione","year":"2015","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2019.111681_bib135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jhet.3426","article-title":"Regioselective N-alkylation of ethyl 4-Benzyloxy-1,2,3-triazolecarboxylate: a useful tool for the synthesis of carboxylic acid bioisosteres","volume":"56","author":"Sainas","year":"2019","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib136","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejmech.2017.02.017","article-title":"Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds","volume":"129","author":"Sainas","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib137","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00894-012-1643-5","article-title":"The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors","volume":"19","author":"Bonomo","year":"2013","journal-title":"J.\u00a0Mol. Model."},{"key":"10.1016\/j.ejmech.2019.111681_bib138","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejmech.2010.10.029","article-title":"1,2,5-Oxadiazole analogues of leflunomide and related compounds","volume":"46","author":"Giorgis","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib139","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejmech.2011.12.038","article-title":"New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold","volume":"49","author":"Lolli","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib140","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ejmech.2018.03.040","article-title":"Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid","volume":"150","author":"Pippione","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib141","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1039\/C7MD00278E","article-title":"4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-\u03baB cascade","volume":"8","author":"Pippione","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2019.111681_bib142","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ejmech.2017.08.046","article-title":"Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach","volume":"139","author":"Pippione","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib143","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsmedchemlett.8b00484","article-title":"Bioisosteres of indomethacin as inhibitors of aldo-keto reductase 1C3","volume":"10","author":"Lolli","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111681_bib144","doi-asserted-by":"crossref","first-page":"328","DOI":"10.20517\/2394-4722.2017.44","article-title":"Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention","volume":"3","author":"Pippione","year":"2017","journal-title":"J.\u00a0Canc. Metastasis Treat."},{"key":"10.1016\/j.ejmech.2019.111681_bib145","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1021\/jm051288b","article-title":"Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of gamma-aminobutyric acid (GABA) related compounds","volume":"49","author":"Lolli","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib146","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00894-008-0269-0","article-title":"Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on \u03b3-aminobutyric acid (GABA) related compounds","volume":"14","author":"Tosco","year":"2008","journal-title":"J.\u00a0Mol. Model."},{"key":"10.1016\/j.ejmech.2019.111681_bib147","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/jm1001452","article-title":"4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues","volume":"53","author":"Lolli","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib148","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejmech.2018.08.094","article-title":"4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric gamma-aminobutyric acid receptor binding site","volume":"158","author":"Giraudo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib149","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1021\/acs.jmedchem.9b00026","article-title":"Five-membered N-heterocyclic scaffolds as novel amino bioisosteres at \u03b3-aminobutyric acid (GABA) type A receptors and GABA transporters","volume":"62","author":"Giraudo","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.111681_bib150","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1021\/acs.jmedchem.8b01986","article-title":"Use of the 4-hydroxy-triazole moiety as a bioisosteric tool in the development of ionotropic glutamate receptor ligands","volume":"62","author":"Sainas","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib151","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1039\/C8MD00068A","article-title":"N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK","volume":"9","author":"Pippione","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2019.111681_bib152","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/jms.3724","article-title":"Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans)","volume":"50","author":"Grossert","year":"2015","journal-title":"J.\u00a0Mass Spectrom."},{"key":"10.1016\/j.ejmech.2019.111681_bib153","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/acsinfecdis.8b00211","article-title":"Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in\u00a0vitro resistance to the clinical candidate DSM265","volume":"5","author":"White","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.111681_bib154","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1021\/acsinfecdis.7b00217","article-title":"Identification of collateral sensitivity to dihydroorotate dehydrogenase inhibitors in plasmodium falciparum","volume":"4","author":"Ross","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.111681_bib155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1292\/jvms.13-0419","article-title":"Babesia bovis dihydroorotate dehydrogenase (BboDHODH) is a novel molecular target of drug for bovine babesiosis","volume":"76","author":"Kamyingkird","year":"2014","journal-title":"J.\u00a0Vet. Med. Sci."},{"key":"10.1016\/j.ejmech.2019.111681_bib156","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.exppara.2017.03.002","article-title":"Effects of dihydroorotate dehydrogenase (DHODH) inhibitors on the growth of Theileria equi and Babesia caballi in\u00a0vitro","volume":"176","author":"Kamyingkird","year":"2017","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2019.111681_bib157","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fmicb.2016.00594","article-title":"Morphological characteristics of schistosoma mansoni PZQ-resistant and -susceptible strains are different in presence of praziquantel","volume":"7","author":"Pinto-Almeida","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2019.111681_bib158","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0163-7258(83)90031-1","article-title":"Purine metabolism in the schistosomes: potential targets for chemotherapy","volume":"20","author":"Senft","year":"1983","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.111681_bib159","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0020-7519(90)90170-R","article-title":"Pyrimidine salvage pathways in adult Schistosoma mansoni","volume":"20","author":"el Kouni","year":"1990","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejmech.2019.111681_bib160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0305-0491(79)90055-5","article-title":"Glutamine-dependent carbamoyl-phosphate synthetase and control of pyrimidine biosynthesis in the parasitic helminth Schistosoma mansoni","volume":"63","author":"Aoki","year":"1979","journal-title":"Comp. Biochem. Physiol. B"},{"key":"10.1016\/j.ejmech.2019.111681_bib161","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0006-2952(72)90064-0","article-title":"Comparative properties of schistosomal and filarial dihydrofolate reductases","volume":"21","author":"Jaffe","year":"1972","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111681_bib162","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0009-2797(99)00144-1","article-title":"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid","volume":"124","author":"Knecht","year":"2000","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2019.111681_bib163","doi-asserted-by":"crossref","first-page":"22467","DOI":"10.1074\/jbc.270.38.22467","article-title":"Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound","volume":"270","author":"Williamson","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111681_bib164","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3835(89)90019-0","article-title":"The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by Brequinar Sodium","volume":"46","author":"de Kant","year":"1989","journal-title":"Cancer Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419308311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419308311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:04:10Z","timestamp":1759327450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419308311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":164,"alternative-id":["S0223523419308311"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111681","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydroorotate dehydrogenase inhibitors in anti-infective drug research","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111681"}}